Journal of Veterinary Science

The Korean Society of Veterinary Science (대한수의학회)
권호 표지
DOI QR코드

DOI QR Code

Aster saponin A2 inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signaling pathway

  • Su, Xiang-Dong (School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University) ;
  • Yang, Seo Y (Department of Pharmaceutical Engineering, Sangji University) ;
  • Shrestha, Saroj K (Department of Dental Pharmacology, School of Dentistry, Jeonbuk National University) ;
  • Soh, Yunjo (Department of Dental Pharmacology, School of Dentistry, Jeonbuk National University)
  • Received : 2021.09.23
  • Accepted : 2022.03.10
  • Published : 2022.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In lipopolysaccharide-induced RAW264.7 cells, Aster tataricus (AT) inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells and MAPKs pathways and critical pathways of osteoclast development and bone resorption. Objectives: This study examined how aster saponin A2 (AS-A2) isolated from AT affects the processes and function of osteoclastogenesis induced by receptor activator of nuclear factor kappa-B ligand (RANKL) in RAW264.7 cells and bone marrow macrophages (BMMs). Methods: The cell viability, tartrate-resistant acid phosphatase staining, pit formation assay, polymerase chain reaction, and western blot were carried out to determine the effects of AS-A2 on osteoclastogenesis. Results: In RAW264.7 and BMMs, AS-A2 decreased RANKL-initiated osteoclast differentiation in a concentration-dependent manner. In AS-A2-treated cells, the phosphorylation of ERK1/2, JNK, and p38 protein expression were reduced considerably compared to the control cells. In RAW264.7 cells, AS-A2 suppressed the RANKL-induced activation of osteoclast-related genes. During osteoclast differentiation, AS-A2 suppressed the transcriptional and translational expression of NFATc1 and c-Fos. AS-A2 inhibited osteoclast development, reducing the size of the bone resorption pit area. Conclusion: AS-A2 isolated from AT appears to be a viable therapeutic therapy for osteolytic illnesses, such as osteoporosis, Paget's disease, and osteogenesis imperfecta.

Keywords

Acknowledgement

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2021R1I1A3055927 to Soh Y), Research Base Construction Fund Support Program funded by Jeonbuk National University in 2021 (Soh Y) and the Ministry of Education, Science and Technology (NRF-2018R1A6A3A11047338 to Yang SY).

References

  1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342. https://doi.org/10.1038/nature01658
  2. Silbermann R, Bolzoni M, Storti P, Guasco D, Bonomini S, Zhou D, et al. Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2014;28(4):951-954. https://doi.org/10.1038/leu.2013.385
  3. Wu M, Chen W, Lu Y, Zhu G, Hao L, Li YP. Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway. Nat Commun. 2017;8(1):1-13. https://doi.org/10.1038/s41467-016-0009-6
  4. Zou W, Reeve JL, Liu Y, Teitelbaum SL, Ross FP. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. Mol Cell. 2008;31(3):422-431. https://doi.org/10.1016/j.molcel.2008.06.023
  5. Ha H, Kwak HB, Le SW, Kim HH, Lee ZH. Lipid rafts are important for the association of RANK and TRAF6. Exp Mol Med. 2003;35(4):279-284. https://doi.org/10.1038/emm.2003.38
  6. Zarei A, Morovat A, Javaid K, Brown CP. Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts. Bone Res. 2016;4(1):16030. https://doi.org/10.1038/boneres.2016.30
  7. Liu W, Zhou L, Zhou C, Zhang S, Jing J, Xie L, et al. GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation. Nat Commun. 2016;7(1):12794. https://doi.org/10.1038/ncomms12794
  8. Wang X, Wei W, Krzeszinski JY, Wang Y, Wan Y. A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab. 2015;22(5):811-824. https://doi.org/10.1016/j.cmet.2015.09.010
  9. Su L, Jiang YY, Liu B. Oligopeptides in plant medicines cited in Chinese pharmacopoeia. Zhongguo Zhong Yao Za Zhi. 2016;41(16):2943-2952.
  10. Yu P, Cheng S, Xiang J, Yu B, Zhang M, Zhang C, et al. Expectorant, antitussive, anti-inflammatory activities and compositional analysis of Aster tataricus. J Ethnopharmacol. 2015;164:328-333. https://doi.org/10.1016/j.jep.2015.02.036
  11. Ma C, Dastmalchi K, Whitaker BD, Kennelly EJ. Two new antioxidant malonated caffeoylquinic acid isomers in fruits of wild eggplant relatives. J Agric Food Chem. 2011;59(17):9645-9651. https://doi.org/10.1021/jf202028y
  12. Su XD, Jang HJ, Li HX, Kim YH, Yang SY. Identification of potential inflammatory inhibitors from Aster tataricus. Bioorg Chem. 2019;92:103208. https://doi.org/10.1016/j.bioorg.2019.103208
  13. Su XD, Jang HJ, Wang CY, Lee SW, Rho MC, Kim YH, et al. Anti-inflammatory potential of saponins from Aster tataricus via NF-κB/MAPK activation. J Nat Prod. 2019;82(5):1139-1148. https://doi.org/10.1021/acs.jnatprod.8b00856
  14. Sapkota M, Li L, Kim SW, Soh Y. Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice. Food Chem Toxicol. 2018;120:418-429. https://doi.org/10.1016/j.fct.2018.07.032
  15. Li L, Sapkota M, Gao M, Choi H, Soh Y. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway. Eur J Pharmacol. 2017;815:202-209. https://doi.org/10.1016/j.ejphar.2017.09.015
  16. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58(3):573-581. https://doi.org/10.1016/0092-8674(89)90438-8
  17. Wu SH, Zhong ZM, Chen JT. Low-magnitude high-frequency vibration inhibits RANKL-induced osteoclast differentiation of RAW264.7 cells. Int J Med Sci. 2012;9(9):801-807. https://doi.org/10.7150/ijms.4838
  18. Park JH, Lee NK, Lee SY. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 2017;40(10):706-713. https://doi.org/10.14348/molcells.2017.0225
  19. Boeyens JC, Deepak V, Chua WH, Kruger MC, Joubert AM, Coetzee M. Effects of ω3- and ω6- polyunsaturated fatty acids on RANKL-induced osteoclast differentiation of RAW264.7 cells: a comparative in vitro study. Nutrients. 2014;6(7):2584-2601. https://doi.org/10.3390/nu6072584
  20. Guo RH, Kim SJ, Choi CH, Na CS, Kang BY, Kim YR. Inhibitory effects of ChondroT and its constituent herbs on RANKL-induced osteoclastogenesis. BMC Complement Altern Med. 2019;19(1):319. https://doi.org/10.1186/s12906-019-2737-8
  21. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-1491. https://doi.org/10.1359/jbmr.0707onj
  22. Cheng D, Shao Y. Terpenoid glycosides from the roots of Aster tataricus. Phytochemistry. 1994;35(1):173-176. https://doi.org/10.1016/S0031-9422(00)90528-4
  23. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature. 2002;416(6882):744-749. https://doi.org/10.1038/416744a
  24. Miyamoto T, Suda T. Differentiation and function of osteoclasts. Keio J Med. 2003;52(1):1-7. https://doi.org/10.2302/kjm.52.1
  25. Lee K, Seo I, Choi MH, Jeong D. Roles of mitogen-activated protein kinases in osteoclast biology. Int J Mol Sci. 2018;19(10):3004. https://doi.org/10.3390/ijms19103004
  26. Nakamura H, Hirata A, Tsuji T, Yamamoto T. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res. 2003;18(7):1198-1205. https://doi.org/10.1359/jbmr.2003.18.7.1198
  27. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology. 2002;143(8):3105-3113. https://doi.org/10.1210/en.143.8.3105
  28. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638-649. https://doi.org/10.1038/nrg1122
  29. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994;266(5184):443-448. https://doi.org/10.1126/science.7939685
  30. Kuroda Y, Matsuo K. Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts. World J Orthop. 2012;3(11):167-174. https://doi.org/10.5312/wjo.v3.i11.167
  31. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202(9):1261-1269. https://doi.org/10.1084/jem.20051150
  32. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7(4):292-304. https://doi.org/10.1038/nri2062
  33. Ikeda K, Takeshita S. The role of osteoclast differentiation and function in skeletal homeostasis. J Biochem. 2016;159(1):1-8. https://doi.org/10.1093/jb/mvv112
  34. Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 2014;21(4):233-241. https://doi.org/10.11005/jbm.2014.21.4.233
  35. Ono T, Nakashima T. Recent advances in osteoclast biology. Histochem Cell Biol. 2018;149(4):325-341. https://doi.org/10.1007/s00418-018-1636-2